DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart ...
WASHINGTON, DC—For patients who present with STEMI complicated by cardiogenic shock (STEMI-CS), it’s not news that the long-awaited DanGer Shock trial showed better 180-day survival after Impella CP ...
Use of two high-risk cardiovascular devices—the Watchman (Boston Scientific) left atrial appendage occluder and the Impella (Abiomed) left ventricular assist device—is highest in the United States ...
Abiomed has issued an urgent medical device correction for its Impella RP and Impella RP Flex series of heart pumps. In a letter sent to customers on January 27, Abiomed said the voluntary device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results